A Phase 1 safety study of GRNOPC1 in patients with neurologically complete, subacute, spinal cord injury

Trial Profile

A Phase 1 safety study of GRNOPC1 in patients with neurologically complete, subacute, spinal cord injury

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Mar 2017

At a glance

  • Drugs OPC 1 (Primary)
  • Indications Spinal cord injuries
  • Focus Adverse reactions; First in man
  • Sponsors Asterias Biotherapeutics
  • Most Recent Events

    • 21 Mar 2017 Results published in an Asterias Biotherapeutics media release.
    • 21 Jun 2016 According to an Asterias Biotherapeutics media release, the results of this trial will be presented at the 2016 International Society for Stem Cell Research (ISSCR) Annual Meeting.
    • 24 May 2016 Positive long-term follow-up results published in Asterias Biotherapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top